NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Timberlyne Therapeutics

Timberlyne Therapeutics

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://timberlyne-tx.com/

Last Round

Series A

Jan 9, 2025

Est. Valuation

$242.6M

Total Funding Raised

$180M

Company Overview

Timberlyne Therapeutics is a biotechnology company that develops and commercializes monoclonal antibody therapies for autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalmonoclonal antibodyautoimmune diseasedrug developmentCD38clinical-stage biotechimmune modulationdrug licensingbiotech startupclinical trialstherapeutic assetsIgG1

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Timberlyne Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Timberlyne Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Timberlyne Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJan 9, 2025

Key People

Founding team and executive leadership

Daniel Curran

Chief Executive Officer

Executive Team

Norbert Schuelke

Chief Technology Officer

Executive Team

Timberlyne Therapeutics Investors

Notable investors and investment history

Timberlyne Therapeutics investors
InvestorRounds
Bain Capital Life SciencesSeries A
Boyu CapitalSeries A
Mountainfield Venture PartnersSeries A
BraidwellSeries A
3H Health InvestmentSeries A
AbingworthSeries A
Lilly Asia VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 9, 2025

    $180M round raised

Timberlyne Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Timberlyne Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Timberlyne Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Diego, California
Employee Range7
Year Founded2024
Last FundingJan 9, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.